The Alabama-based TransMolecular Inc is a privately held neuroscience biotechnology company that specializes in discovering, developing, and commercializing novel and proprietary drugs to diagnose and treat diseases of the central nervous system. With a strong management team that has over 75 years of combined relevant experience in healthcare, pharmaceutical development, R&D, operations, and finance, the company has built strong technology platforms to enrich its product discovery and development pipeline. TransMolecular has raised $9.6MM to date through two private placements from internationally recognized investment firms and has received three Small Business Incentive Research grants totaling $1 million from the National Institutes of Health for its cancer and pain programs. The company offers TM601, a synthetic polypeptide based on amino acid peptide derived from scorpion venom, which is used to treat cancer, specifically glioma, metastatic brain tumors, and cancers. TransMolecular holds more than 25 patents and/or patent applications to protect its products worldwide and has exclusive license agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its cancer and pain technology, respectively.